Mesothelioma Clinical Trial Studies Keytruda, Lenvatinib Combination

The objective response rate of the Keytruda/lenvatinib combination was an impressive 58%. In 2020, the U.S. Food and Drug Administration approved the use of Keytruda for certain metastatic tumors, including certain cases of mesothelioma, but the search for an effective combination continues. Lenvatinib has shown it can block tumor growth by targeting specific proteins Keytruda can’t reach. It has been effective with only select cancers and is known as precision medicine. The drug, which is already FDA approved, has been used successfully with Keytruda for the treatment of endometrial cancer. Lenvatinib is prescribed alone to treat hepatocellular carcinoma, a type of liver cancer. It is used in other combinations to help treat renal cell carcinoma. Searching for Second-Line Mesothelioma Treatments  The need for second-line treatments of unresectable mesothelioma is ongoing. The average life expectancy of someone with the disease is 12 to 21 months. Pleural mesothelioma is a rare cancer caused mostly by long-ago inhalation or ingestion of asbestos fibers. It is diagnosed in an estimated 3,000 people annually in the U.S. The FDA approved the immunotherapy combination of Opdivo and Yervoy in 2020 for first-line treatment, adding to standard-of-care chemotherapy. Neither treatment, though, has shown an ability to be effective long-term for most patients. “Despite many trials and a list of recommendations, there is still no standard treatment in the...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Clinical Trials/Research/Emerging Treatments Pleural Source Type: news